The domestic and overseas listing status and price of fenelidone

Finerenoneis a nonsteroidal selective mineralocorticoid receptor antagonist used to treat patients with type 2 diabetes associated with chronic kidney disease. The research and development of this drug was led by Bayer AG in Germany. It was approved for marketing by the US FDA on July 9, 2021, under the trade name Kerendia. It was subsequently approved by the EMA on March 11, 2022, further establishing its global treatment status. In the Chinese market, fenelidone was approved by the State Food and Drug Administration in June 2022 and is sold by Bayer under the name of "Kerendia" or Kerendia, becoming a new choice for domestic kidney disease patients.

In China, the original drug of fenelidone has been successfully included in the Class B National Medical Insurance List, which means that patients who meet the indications can enjoy a certain proportion of medical insurance reimbursement when using the drug, reducing their financial burden. At present, common specifications are 10 mg × 14 tablets and 20 mg × 7 tablets. The price per box is between a few hundred yuan. The proportion of self-payment after medical insurance may vary greatly depending on regional policies.

In comparison, the overseas price of fenelidone is much higher. For example, the American, European or Japanese versions are obviously more expensive. The Japanese versionThe price of 100-piece Kerendia may be around RMB 2,000, and the specific amount will also be affected by real-time exchange rate fluctuations. In addition, there are also generic versions from multiple sources overseas. Generic versions of fenelidone produced in regions such as Laos and India are relatively low-priced because they are not subject to original research protection restrictions. For example, a package of 30 tablets may be sold for about 200 yuan, but the efficacy and quality need to be carefully evaluated.

Overall, the accessibility of fenelidone is constantly improving, both in China and overseas. Especially after the original drug was launched in China and included in the medical insurance catalog, patients with type 2 diabetes-related kidney disease have more diversified treatment options, which also reduces the economic pressure caused by long-term medication.

Reference materials:https://www.kerendia.com/